Abstrakt

Anthracycline-related Acute Cardiotoxicity in a very young Omani patient with Acute Myeloid Leukemia

Surekha Tony Mevada, Niranjan Joshi, Khalfan Al Senaidi and Yasser Wali

Daunorubicin, an anthracycline antibiotic is widely used in the treatment of acute myeloid leukemia (AML). Anthracycline related cardiotoxicity (ACT) remains a major concern for survivors of childhood AML 1. It can present as early cardiac dysfunction with onset during or shortly after chemotherapy or as chronic impairment of cardiac function several years after treatment 2. It usually progresses from cardiomyocyte injury to silent left ventricular dysfunction which often becomes symptomatic and irreversible 3. Predictors of cardiotoxicity include age at time of diagnosis, cumulative anthracycline dosage, and cardiovascular risk factors